Tung, Nadine
Garber, Judy E
Hacker, Michele R
Torous, Vanda
Freeman, Gordon J
Poles, Emily
Rodig, Scott
Alexander, Brian
Lee, Larissa
Collins, Laura C
Schnitt, Stuart J
Article History
Received: 11 November 2015
Accepted: 28 December 2015
First Online: 24 February 2016
Competing interests
: G.J.F. has patents/pending royalties on the PD-1 pathway from Bristol-Myers-Squibb, Roche, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca and Novartis and has a patent application for the use of 9A11 antibody for diagnostic purposes. G.J.F. has served on advisory boards for CoStim, Novartis, Roche, and Bristol-Myers-Squibb. The remaining authors declare no conflict of interest.